Wireless Retinal Implant Restores Vision in AMD Patients: Clinical Trial Results

A groundbreaking wireless retinal implant is offering a new prospect for individuals grappling with vision loss due to advanced age-related macular degeneration (AMD). Published in the New England Journal of Medicine, recent clinical trial results demonstrate that the device, known as the PRIMA system, can restore central vision in some patients with the advanced “geographic atrophy” form of the disease, which affects over 5 million people globally.

The implant represents a significant step forward in vision restoration, a field that has historically faced considerable challenges. Unlike previous approaches, the PRIMA system aims to bypass damaged light-sensing cells, directly stimulating the remaining functioning retinal cells to transmit visual information to the brain. This is achieved through a 2×2 mm wireless implant paired with specially designed glasses.

How the PRIMA System Works

In a healthy eye, light enters and is captured by photoreceptor cells in the retina. These cells convert the light into electrical signals, which are then sent via the optic nerve to the brain, allowing us to notice. In geographic atrophy (GA), a late-stage form of AMD, these crucial photoreceptors progressively die, leading to a loss of central vision – impacting activities like reading, driving, and recognizing faces.

The PRIMA system, originally conceived by Daniel Palanker, Ph.D., at Stanford University, addresses this issue by acting as an artificial retina. The glasses contain a camera that captures images and transmits them to the implant using near-infrared light. The implant then converts this light into electrical signals, stimulating the remaining viable retinal cells and effectively relaying visual information to the brain. Users can similarly adjust settings on the glasses to optimize zoom and contrast for clearer vision. The New England Journal of Medicine published the full study details on October 20, 2025.

Significant Vision Gains in Clinical Trials

The international, multi-center clinical trial, co-led by José-Alain Sahel, M.D. Of the UPMC Vision Institute, involved 38 participants aged 60 and older across France, Germany, Italy, the Netherlands, and the United Kingdom. Data from 32 participants who completed 12 months of follow-up revealed encouraging results.

A substantial 81% of participants – 26 individuals – experienced clinically meaningful improvements in visual acuity. 84% (27 participants) reported utilizing the prosthetic vision system at home for everyday tasks like reading numbers and words. On average, participants demonstrated a gain of 25 letters on a standard eye chart, equivalent to approximately five lines of improved vision. Remarkably, 81% of participants gained at least 10 letters. One participant even experienced an improvement of 59 letters, representing a 12-line gain. University of Pittsburgh Medical Center News provides further details on the trial’s methodology and outcomes.

“It’s the first time that any attempt at vision restoration has achieved such results in a large number of patients,” stated Sahel, who also chairs the Department of Ophthalmology at the University of Pittsburgh School of Medicine. “More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book. This is really something we couldn’t have dreamt of when we started on this journey, together with Daniel Palanker, 15 years ago.”

Understanding Geographic Atrophy and AMD

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in older adults. Geographic atrophy (GA) represents the advanced, “dry” form of AMD, characterized by the progressive death of cells in the macula – the central part of the retina responsible for sharp, detailed vision. While there are treatments available to unhurried the progression of the “wet” form of AMD, there have been limited options for those with GA until now. UPMC Physician Resources offers a concise overview of AMD and the impact of GA.

Limitations and Future Directions

While the results of the PRIMAvera trial are promising, it’s important to acknowledge the study’s limitations. The improvements in vision, while significant, do not restore full 20/20 vision. The device currently enhances central vision, but peripheral vision remains unaffected. The long-term durability and safety of the implant require continued monitoring.

Researchers at UPMC are now exploring ways to further enhance the effectiveness of the implant, aiming to improve visual acuity beyond the threshold for legal blindness. The device manufacturer, Science Corporation, has submitted applications for clinical use approval in both Europe and the United States, following the positive trial outcomes. UPMC was the first U.S. Center to implant the PRIMA device in 2020 as part of an earlier study.

Regulatory Process and Availability

The submission of applications to regulatory bodies marks a crucial step toward making the PRIMA system more widely available to patients with GA. The review process will involve a thorough evaluation of the clinical trial data, safety profiles, and manufacturing processes. If approved, the implant could offer a life-changing option for individuals who have previously had limited treatment options.

The study was funded by Science Corporation, formerly Pixium Vision SA, highlighting the role of industry investment in driving innovation in vision restoration technologies. The research team included collaborators from multiple institutions across Europe and the United States, demonstrating the collaborative nature of this scientific endeavor.

What comes next: The coming months will be critical as regulatory agencies assess the data submitted by Science Corporation. Patients and clinicians will be closely watching for updates on the approval process and potential timelines for wider availability of the PRIMA system. Continued research will also focus on optimizing the device and exploring its potential in combination with other therapies to further improve vision outcomes for individuals with geographic atrophy.